Siddharth Kunte
YOU?
Author Swipe
View article: Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations Open
View article: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations Open
RET receptor tyrosine kinase is activated in various cancers (lung, thyroid, colon and pancreatic, among others) through oncogenic fusions or gain-of-function single-nucleotide variants. Small-molecule RET kinase inhibitors became standard…
View article: Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer Open
View article: Demographic disparities in trend of gynecological cancer in the United States
Demographic disparities in trend of gynecological cancer in the United States Open
View article: Changes in CT radiomic features predict survival and early response to CDK 4/6 inhibitors in hormone receptor positive metastatic breast cancer
Changes in CT radiomic features predict survival and early response to CDK 4/6 inhibitors in hormone receptor positive metastatic breast cancer Open
Background The combination of Cyclin-dependent kinase 4/6 inhibitors (CDKi) and endocrine therapy (ET) is the standard of care for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast…
View article: Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes
Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes Open
Advanced T and N stage were factors associated with significantly inferior outcomes. While select patients benefited with systemic treatment, it remains unclear if intensified locoregional therapy should be considered in patients with PDTC.
View article: Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling Open
Desmoplastic small round cell tumor (DSRCT) is characterized by the t(11;22)(p13;q12) translocation, which fuses the transcriptional regulatory domain of EWSR1 with the DNA-binding domain of WT1, resulting in the oncogenic EWSR1-WT1 fusion…
View article: Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study Open
View article: Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes Open
Background Recent evidence suggests a rising incidence of cancer in younger individuals. Herein, we report the epidemiologic, pathologic, and molecular characteristics of a patient cohort with early-onset pancreas cancer (EOPC). Methods In…
View article: RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation Open
Multi-kinase RET inhibitors, such as cabozantinib and RXDX-105, are active in lung cancer patients with RET fusions; however, the overall response rates to these two drugs are unsatisfactory compared to other targeted therapy paradigms. Mo…
View article: Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach
Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach Open
Desmoplastic small round cell tumor (DSRCT) is characterized by the t(11;22)(p13;q12) chromosomal translocation, which fuses the transcriptional regulatory domain of EWSR1 with the zinc finger DNA-binding domain of WT1 , resulting in the o…
View article: Novel HER2–targeted therapies for HER2–positive metastatic breast cancer
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer Open
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of all breast cancers. Before the development of HER2‐directed monoclonal antibodies, HER2–positive breast cancer was associated with a rather poor progn…
View article: Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?
Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers? Open
MET is a well described proto-oncogene. It was first identified in the 1980s, and its ligand, hepatocyte growth factor (HGF), was later identified in the early 1990s. MET is activated when HGF binds to the receptor, inducing homodimerizat…
View article: Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score Open